| Wenwu Wang,Shanshan Huang,Xiaoyan Huang,Yan Zhang,Xiaoyan Qi. Clinical observation of rh-endostatin combined with chemotherapy as first line treatment for metastatic colorectal cancer. Oncol Transl Med, 2016, 2: 279-284. |
| Clinical observation of rh-endostatin combined with chemotherapy as first line treatment for metastatic colorectal cancer |
| Received:June 16, 2016 Revised:November 22, 2016 |
| View Full Text View/Add Comment Download reader |
| KeyWord:rh-endostatin; FOLFOX4 regimen; metastatic colorectal cancer |
| Author Name | Affiliation | E-mail | | Wenwu Wang | Department of oncology,Nanjing Military Command Fuzhou General Hospital,Fuzhou, Department of oncology,Central Hospital of Zibo,Communist Youth League Road#$NBS Zhangdian#$NBSdistrict,Zibo#$NBScity,Shandong,#$NBS | 1275452403@qq.com | | Shanshan Huang | Department of oncology,Nanjing Military Command Fuzhou General Hospital,Fuzhou, Department of oncology,Central Hospital of Zibo,Communist Youth League Road#$NBS Zhangdian#$NBSdistrict,Zibo#$NBScity,Shandong,#$NBS | 1275452403@qq.com | | Xiaoyan Huang | Department of oncology,Nanjing Military Command Fuzhou General Hospital,Fuzhou, Department of oncology,Central Hospital of Zibo,Communist Youth League Road#$NBS Zhangdian#$NBSdistrict,Zibo#$NBScity,Shandong,#$NBS | 1275452403@qq.com | | Yan Zhang | Department of oncology,Nanjing Military Command Fuzhou General Hospital,Fuzhou, Department of oncology,Central Hospital of Zibo,Communist Youth League Road#$NBS Zhangdian#$NBSdistrict,Zibo#$NBScity,Shandong,#$NBS | 1275452403@qq.com | | Xiaoyan Qi | Department of Oncology,Central Hospital of Zibo，Communist Youth League Road 54 Zhangdian district, Zibo city, Shandong, 255036，China | 1275452403@qq.com |
|
| Hits: 6758 |
| Download times: 7358 |
| Abstract: |
| Objective To analyze the efficacy and safety of Rh-endostatin combined with chemotherapy in the
treatment of metastatic colorectal cancer.
Methods All 60 metastatic colorectal cancer patients were divided into the test group (n = 30) and the
control group (n = 30). The control group was treated with chemotherapy regime FOLFOX4 (Oxaliplatin
Fluorouracil Calcium Levofolinate), the test group was treated by Endostar combined with FOLFOX4
scheme.
Results The response rates were 53.3% in test group and 36.7% in control group respectively (P < 0.05),
the disease control rate were 83.3% and 73.3% (P < 0.05). The median progression-free survival in test
group and control group were 7.3 months versus 5.3 months (P < 0.05) and median overall survival were
11.6 months versus 9.3 months (P < 0.05). Among 27 cases of liver metastases were sub group analysis,
difference on the test group and the control group response rate (RR) and disease control rate (DCR) had
statistical significance (P < 0.05), but difference on progression free survival (PFS) and overall survival
(OS) had no statistical significance (P > 0.05). The major toxicities were myelosuppression, gastrointestinal
symptoms, neurotoxicity, most in grade I-II. After chemotherapy, quality of life (QOL) of patients were more
improved than before treatment. After treatment the carcino embryonie antigen (CEA) and caner antigent
199 (CA199) levels decreased obviously, furthermore, the test group decreased more obviously than the
control group.
Conclusion Rh-endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer
is safer and effective, and also improves PFS. |
| Close |
|
|
|